Evident has completed the acquisition of CrestOptics, a leading developer and manufacturer of advanced optical imaging systems for spinning disk confocal and super-resolution microscopy. The transaction expands Evident’s life science imaging portfolio and strengthens its capabilities in high-speed, high-content imaging applications serving research, pharmaceutical and biotechnology customers.

About Evident
Evident is a global leader in microscopy and imaging solutions, serving life science, clinical and industrial end markets through a broad portfolio of advanced microscopy, digital imaging and analytical instrumentation products. This engagement reflects EC M&A’s longstanding relationship with Bain Capital and Evident, building on our advisory role in the divestiture of Evident’s Test & Measurement business and reinforcing our position as a trusted advisor across the platform.

About CrestOptics
Founded in Rome, Italy, CrestOptics develops advanced optical imaging systems, including spinning disk confocal and super-resolution microscopy platforms that enable high-speed, high-contrast imaging for life science research applications. Its technologies are used by leading research institutions, pharmaceutical companies and biotechnology organizations worldwide.

EC M&A served as exclusive financial advisor to Evident on this transaction.